Biomarin Pharmaceutical (BMRN) EPS (Basic) Growth (1y) (2010 - 2026)
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) EPS (Basic) Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 87.85% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 143.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 322.67% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -16.29% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | -81.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -81.54% |
| Mar 31, 2026 | -43.62% |
| Dec 31, 2025 | -136.93% |
| Sep 30, 2025 | -128.74% |
| Jun 30, 2025 | 122.33% |
| Mar 31, 2025 | 107.13% |
| Dec 31, 2024 | 506.14% |
| Sep 30, 2024 | 159.67% |
| Jun 30, 2024 | 89.07% |
| Mar 31, 2024 | 72.32% |
| Dec 31, 2023 | 8,170.86% |
| Sep 30, 2023 | 698.55% |
| Jun 30, 2023 | 99.67% |
| Mar 31, 2023 | -58.51% |
| Dec 31, 2022 | 99.58% |
| Sep 30, 2022 | 82.01% |
| Jun 30, 2022 | 110.99% |
| Mar 31, 2022 | 587.02% |
| Dec 31, 2021 | -436.21% |
| Sep 30, 2021 | -104.60% |